即时脂质检测市场－全球产业规模、份额、趋势、机会和预测（按产品、应用、疾病适应症、最终用户、地区和竞争细分，2020 年至 2030 年）

2024 年全球即时血脂检测市场规模为 7.3561 亿美元，预计到 2030 年将达到 10.7248 亿美元，复合年增长率为 6.46%。受心血管疾病发病率上升和早期血脂检测日益重要的推动，该市场正在稳步扩张。即时血脂检测 (POC) 可提供快速、准确的诊断，支援在初级保健和急诊环境中及时做出临床决策。人们的健康意识不断增强以及对预防保健的重视加速了即时血脂检测的普及，这种检测因其易用性和诊断价值而受到医生和患者的青睐。即时血脂检测与行动诊所和社区药局的整合进一步提高了其可近性。具有蓝牙和云端功能的便携式血脂分析仪的进步也正在改变患者监测以及资料与电子健康记录的整合方式。可同时检测多种生物标记的多分析物平台的需求正在增长，这与向分散诊断和基于价值的医疗保健服务的转变相辅相成。

关键市场驱动因素

心血管疾病和血脂异常盛行率上升

主要市场挑战

对准确性和可靠性的担忧

主要市场趋势

数位健康科技的整合

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球即时脂质测试市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按产品（仪器、耗材）
  • 依应用（高血脂、高三酸甘油脂血症、丹吉尔氏症、高脂蛋白血症、家族性高胆固醇血症、其他）
  • 依疾病适应症（脂质和脂蛋白疾病、动脉粥状硬化、肝肾疾病、糖尿病、其他）
  • 按最终使用者（医院、诊所、研究和诊断实验室等）
  • 按公司分类（2024）
  • 按地区
• 市场地图

第六章：北美即时脂质检测市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲即时脂质测试市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区即时脂质检测市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第九章：南美洲即时脂质检测市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲即时脂质测试市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如有）
• 最新动态

第十三章：干扰：衝突、流行病与贸易壁垒

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• Callegari Srl
• Sinocare Inc.
• Abbott Laboratories
• MiCoBio
• Nova Biomedical
• VivaChek Biotech (Hangzhou) Co., Ltd.
• F. Hoffmann-La Roche Ltd.
• Menarini Group
• SD Biosensor, Inc.
• Becton, Dickinson and Company

第 16 章：策略建议

第17章调查会社について・免责事项

The Global Point of Care Lipid Test Market was valued at USD 735.61 Million in 2024 and is projected to reach USD 1072.48 Million by 2030, registering a CAGR of 6.46%. The market is expanding steadily, driven by the rising incidence of cardiovascular diseases and the growing importance of early lipid level detection. Point-of-care (POC) lipid testing offers rapid, accurate diagnostics, supporting timely clinical decisions in primary care and emergency settings. Increasing health awareness and emphasis on preventive care have accelerated the adoption of POC lipid tests, which are gaining popularity among both physicians and patients for their ease of use and diagnostic value. Their integration into mobile clinics and community pharmacies further enhances accessibility. Advancements in portable lipid analyzers with Bluetooth and cloud capabilities are also transforming patient monitoring and data integration with electronic health records. The demand for multi-analyte platforms that test for multiple biomarkers simultaneously is on the rise, complementing the shift toward decentralized diagnostics and value-based healthcare delivery.

Key Market Drivers

Rising Prevalence of Cardiovascular Diseases and Dyslipidemia

The increasing global burden of cardiovascular diseases (CVDs) and dyslipidemia is a primary driver of the Point of Care (POC) Lipid Test Market. Conditions such as coronary artery disease, hypertension, and stroke remain among the leading causes of death. Dyslipidemia, defined by abnormal cholesterol or triglyceride levels, is a major risk factor. In 2020, nearly 12% of U.S. adults had high total cholesterol, with over 38% displaying borderline or elevated levels. POC lipid testing allows for immediate results, enabling prompt therapeutic actions like prescribing statins or initiating lifestyle interventions. These tests are especially beneficial in primary care, outpatient clinics, and community screenings, helping improve patient compliance and supporting proactive cardiovascular risk management. Public health campaigns have also incorporated POC lipid testing, particularly in rural and underserved areas.

Key Market Challenges

Concerns Regarding Accuracy and Reliability

A notable challenge for the POC lipid test market is the ongoing concern over test accuracy and reliability compared to laboratory-based diagnostics. While the convenience and speed of POC tests are appealing, variability in calibration, operator handling, and environmental conditions can compromise test performance. These inconsistencies may lead to incorrect readings, influencing clinical decisions and potentially affecting patient safety. The diagnostic accuracy of some devices remains under scrutiny, particularly in uncontrolled environments, creating hesitation among clinicians and regulatory bodies. The lack of standardized manufacturing practices and rigorous quality validation also impacts market confidence. In lower-resource settings, insufficient training and infrastructure further limit the reliability of test outcomes. Addressing these concerns will require standardized quality benchmarks, broader training programs, and enhanced device design to match lab-grade diagnostic standards.

Key Market Trends

Integration of Digital Health Technologies

The market is undergoing a digital transformation as point-of-care lipid testing devices increasingly integrate with digital health technologies. These devices now feature real-time data transfer capabilities to electronic health records (EHRs), enhancing clinical decision-making and workflow efficiency. Cloud-based systems support centralized data storage, remote access, and predictive analytics, enabling proactive risk management. Smartphone-compatible devices and mobile health applications allow patients to track cholesterol levels, medication adherence, and lifestyle habits from home, fostering a more engaged and personalized approach to lipid management. Artificial intelligence (AI) and machine learning (ML) tools are also being introduced to interpret test data more accurately and identify complex risk patterns. These innovations align with value-based care strategies and are particularly valuable in supporting long-term disease prevention and management.

Key Market Players

• Callegari Srl
• Sinocare Inc.
• Abbott Laboratories
• MiCoBio
• Nova Biomedical
• VivaChek Biotech (Hangzhou) Co., Ltd.
• F. Hoffmann-La Roche Ltd.
• Menarini Group
• SD Biosensor, Inc.
• Becton, Dickinson and Company

Report Scope

In this report, the Global Point of Care Lipid Test Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Point of Care Lipid Test Market, By Product:

• Instruments
• Consumables

Point of Care Lipid Test Market, By Application:

• Hyperlipidemia
• Hypertriglyceridemia
• Tangier Disease
• Hyperlipoproteinemia
• Familial Hypercholesterolemia
• Others

Point of Care Lipid Test Market, By Disease Indication:

• Lipid and Lipoprotein Disorders
• Atherosclerosis
• Liver and Renal Diseases
• Diabetes Mellitus
• Others

Point of Care Lipid Test Market, By End User:

• Hospitals
• Clinics
• Research and Diagnostic Laboratories
• Others

Point of Care Lipid Test Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Point of Care Lipid Test Market.

Available Customizations

Global Point of Care Lipid Test Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Point of Care Lipid Test Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Consumables)
  • 5.2.2. By Application (Hyperlipidemia, Hypertriglyceridemia, Tangier Disease, Hyperlipoproteinemia, Familial Hypercholesterolemia, Others)
  • 5.2.3. By Disease Indication (Lipid and Lipoprotein Disorders, Atherosclerosis, Liver and Renal Diseases, Diabetes Mellitus, Others)
  • 5.2.4. By End User (Hospitals, Clinics, Research and Diagnostic Laboratories, Others)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Point of Care Lipid Test Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Disease Indication
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Point of Care Lipid Test Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Disease Indication
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico Point of Care Lipid Test Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Disease Indication
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada Point of Care Lipid Test Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Disease Indication
      • 6.3.3.2.4. By End User

7. Europe Point of Care Lipid Test Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Disease Indication
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Point of Care Lipid Test Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Disease Indication
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Point of Care Lipid Test Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Disease Indication
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Point of Care Lipid Test Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Disease Indication
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Point of Care Lipid Test Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Disease Indication
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Point of Care Lipid Test Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Disease Indication
      • 7.3.5.2.4. By End User

8. Asia-Pacific Point of Care Lipid Test Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Disease Indication
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Point of Care Lipid Test Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Disease Indication
      • 8.3.1.2.4. By End User
  • 8.3.2. India Point of Care Lipid Test Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Disease Indication
      • 8.3.2.2.4. By End User
  • 8.3.3. South Korea Point of Care Lipid Test Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Disease Indication
      • 8.3.3.2.4. By End User
  • 8.3.4. Japan Point of Care Lipid Test Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Disease Indication
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Point of Care Lipid Test Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Disease Indication
      • 8.3.5.2.4. By End User

9. South America Point of Care Lipid Test Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Disease Indication
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Point of Care Lipid Test Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Disease Indication
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Point of Care Lipid Test Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Disease Indication
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Point of Care Lipid Test Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Disease Indication
      • 9.3.3.2.4. By End User

10. Middle East and Africa Point of Care Lipid Test Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Disease Indication
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Point of Care Lipid Test Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Disease Indication
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Point of Care Lipid Test Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Disease Indication
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Point of Care Lipid Test Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Disease Indication
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Callegari Srl
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Sinocare Inc.
• 15.3. Abbott Laboratories
• 15.4. MiCoBio
• 15.5. Nova Biomedical
• 15.6. VivaChek Biotech (Hangzhou) Co., Ltd.
• 15.7. F. Hoffmann-La Roche Ltd.
• 15.8. Menarini Group
• 15.9. SD Biosensor, Inc.
• 15.10. Becton, Dickinson and Company

16. Strategic Recommendations

17. About Us & Disclaimer